- Home
- GDST vs IKT Comparison
GDST vs IKT Comparison
Compare GDST & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDST
- IKT
- Stock Information
- Founded
- GDST 2020
- IKT 2008
- Country
- GDST United States
- IKT United States
- Employees
- GDST N/A
- IKT N/A
- Industry
- GDST
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- GDST
- IKT Health Care
- Exchange
- GDST NYSE
- IKT Nasdaq
- Market Cap
- GDST N/A
- IKT 159.2M
- IPO Year
- GDST 2022
- IKT 2020
- Fundamental
- Price
- GDST $11.29
- IKT $3.42
- Analyst Decision
- GDST
- IKT Strong Buy
- Analyst Count
- GDST 0
- IKT 2
- Target Price
- GDST N/A
- IKT $6.50
- AVG Volume (30 Days)
- GDST 125.0
- IKT 471.4K
- Earning Date
- GDST 01-01-0001
- IKT 11-14-2024
- Dividend Yield
- GDST N/A
- IKT N/A
- EPS Growth
- GDST 111.15
- IKT N/A
- EPS
- GDST 0.23
- IKT N/A
- Revenue
- GDST N/A
- IKT $1.00
- Revenue This Year
- GDST N/A
- IKT N/A
- Revenue Next Year
- GDST N/A
- IKT N/A
- P/E Ratio
- GDST $49.87
- IKT N/A
- Revenue Growth
- GDST N/A
- IKT N/A
- 52 Week Low
- GDST $10.73
- IKT $1.12
- 52 Week High
- GDST $12.45
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- GDST 80.29
- IKT 52.41
- Support Level
- GDST N/A
- IKT $3.12
- Resistance Level
- GDST $11.31
- IKT $4.20
- Average True Range (ATR)
- GDST 0.00
- IKT 0.42
- MACD
- GDST 0.01
- IKT -0.00
- Stochastic Oscillator
- GDST 81.82
- IKT 30.67
About GDST GOLDENSTONE ACQUISITION LIMITED
Goldenstone Acquisition Ltd is a newly organized blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.